Published in final edited form as:

Tetrahedron. 2001 July 23; 57(30): 6329–6343. doi:10.1016/S0040-4020(01)00499-9.

Stereocontrolled Synthesis of Quaternary β,γ -Unsaturated Amino Acids: Chain Extension of D- & L- α -(2-Tributylstannyl)Vinyl Amino Acids

David B. Berkowitz, Esmort Chisowa, and Jill M. McFadden

Department of Chemistry, University of Nebraska, Lincoln, NE 68588-0304

Abstract

A pair of diastereomeric (4S,5S)- and (4S,5R)-4-methoxycarbonyl-5-phenylselenomethyl-2-phenyl oxazolines, derived from L-vinylglycine, serve as precursors to protected, quaternary, L- and D- α -(2-tributylstannyl)vinyl amino acids, respectively, in three steps {(i) alkylative side chain installation, (ii) eliminative ring-opening and (iii) vinyl selenide to vinyl stannane interconversion}. The title compounds may be protodestannylated to the corresponding free, quaternary L- and D-vinyl amino acids. Alternatively, the 2-stannylvinyl α -branch (or the derivative 2-iodovinyl branch) may be exploited to access novel quaternary, L- and D- β,γ -unsaturated amino acids via a range of transition metal-mediated cross coupling reactions.

Keywords

self regeneration of stereocenters (SRS); β ; γ -unsaturated amino acids; vinyl selenides; vinyl stannanes; chain extension

INTRODUCTION

Nature produces a number of β,γ -unsaturated amino acids, generally bearing an α -hydrogen.¹ The simplest member of this family, α -vinylglycine (**1**), has been isolated from mushroom sources.² Such amino acids are potential mechanism-based inactivators (MBI's) for enzymes that process amino acids by first removing the α -proton, including racemases, transaminases, and β - and γ -elimination and replacement enzymes. Indeed, vinylglycine is known to inactivate transaminases for L-aspartate, L-alanine, L-serine and D-alanine,^{3a-e} as well as cysteine sulfinatase decarboxylase.⁴ Incorporation of D-vinylglycine into an appropriate peptide leads to inhibition of peptidylglycine α -hydroxylating monooxygenase.⁵

Another member of this family, APPA (2-amino-5-phosphono-3-pentenoic acid (**2**); the β,γ -unsaturated phosphonate analogue of homoserine phosphate), inactivates the β -elimination enzyme, threonine synthase.⁶ E-APPA inhibits the γ -replacement enzyme, cystathionine γ -synthase.⁷ But perhaps the most well-studied example of an amino acid bearing unsaturation β - and γ - to the amino group that acts as a mechanism-based inhibitor is vigabatrin (**3**, γ -vinyl GABA). Vigabatrin inactivates GABA transaminase,⁸ thereby raising brain GABA levels. This drug has seen extensive clinical use as an anti-epileptic⁹ and, quite recently, has shown promise as a potential alternative to (methadone) replacement therapy in the treatment of substance addiction.¹⁰

If one wishes to apply a similar vinyl-triggering strategy to the mechanism-based inactivation of amino acid decarboxylase (AADC) enzymes, *quaternary* β,γ -unsaturated amino acids become attractive targets. That is, the usual AA side chain functional group is retained, to direct the inhibitor to the active site of interest, and an α -decarboxylation event, rather than an α -deprotonation event, is expected to conjugate the otherwise unreactive C-C double bond with the quinonoid intermediate along the PLP-enzyme reaction coordinate.¹¹ Adding to the value of this family of *higher*¹² α -vinyl AA's, we have found that they conveniently serve as precursors to previously unexplored classes of potential AADC MBI's, including α -oxiranyl,¹³ α -(2Echloro) vinyl,¹⁴ α -(1-chloro)vinyl¹⁴ and α -(2Z-fluoro)vinyl¹⁵ amino acids (Scheme 2).

The divergency of this approach is attractive from a tactical point of view, both in terms of overall synthetic efficiency and in terms of stereochemical control. That is, given the stability of these quaternary AA's to racemization, control of absolute stereochemistry in the construction of the parent higher α -vinyl amino acids should translate into stereochemical control for all such derivative classes, as well. The ability to generate a variety of α -branched AA's from parent α -vinyl or α -stannylvinyl AA's also has implications for unnatural amino acid mutagenesis¹⁶ and for combinatorial chemistry. In the latter case, libraries of α -amino acids are often used and library diversity is a variable of great import.¹⁷ Indeed, it may be advantageous to broaden the number and type of quaternary AA's included in such AA libraries, as α -branched AA's, including those bearing unsaturation,¹⁸ tend to promote peptidyl secondary structure, particularly α -helical, and 3¹⁰-helical motifs.¹⁹ At the same time, these unnatural AA's often confer resistance to proteolysis upon their derivative peptides.²⁰ In fact, of late, great success has been achieved with α -branched AA's for the design of short peptides (i) that fold into helical structures in aqueous solution,¹⁹ (ii) that bind to receptors,^{20a,21} or (iii) that catalyze chemical reactions.²²

ENANTIOSELECTIVE SYNTHESIS OF β,γ -UNSATURATED AA'S

For most of the applications enumerated in the *Introduction*, scalemic α -branched amino acids, of known handedness are preferable.²³ This article will focus on the asymmetric synthesis of AA's bearing a β,γ -unsaturation. At the outset, we wish to highlight several particularly elegant enantiocontrolled syntheses of β,γ -unsaturated AA's for systems in which an α -proton is present (substituted alkenylglycines). From there, the discussion will move into a summary of available methods for the stereocontrolled construction of *quaternary* β,γ -unsaturated AA's. Among these, the title α -(2-tributylstannyl)vinyl AA's are especially attractive, as these are available in either D- or L-form, and lead either to unsubstituted α -vinyl AA's (protodestannylation) or to more complex, chain-extended congeners, as desired.

I. Substituted Alkenylglycines

As noted before, the simplest β,γ -unsaturated vinyl AA is vinylglycine itself, for which a good number of asymmetric syntheses have been developed.²⁴ Derivatives of vinylglycine in which the double bond bears one or more substituents, but in which the α -proton is retained, will be termed alkenylglycines here.

R. M. Williams and coworkers described a nice route to such compounds that passes through an interesting class of β,γ -alkynylglycines.²⁵ The same 4,5-diphenyl-1,4-oxazin-2-one template that serves as the basis of Williams' chiral glycine enolate equivalent, provides for a chiral electrophilic glycine equivalent here. Condensation of **4** with trialkylstannylalkynes leads to the protected α -alkynyl AA's **5**, presumably via the intermediacy of the corresponding α -iminium ion (Scheme 3).^{25a} The alkyne is then reduced under dissolving metal conditions, with $\text{Na}^0\text{-NH}_3(\text{l})$ giving the higher chemical yields, but with $\text{Li}^0\text{-NH}_3(\text{l})$ giving better optical yields.

O'Donnell has developed the related electrophilic glycine equivalent, **7**. This system is cleverly outfitted with the benzophenone imine protecting group on nitrogen, allowing for Pd-mediated allylic substitution at the α -carbon. Transmetalation can be effected with in situ-generated vinylaluminum reagents, thereby providing alkenylglycines directly.^{26a} This cross-coupling chemistry was carried out in racemic fashion initially, but more recent developments suggest that enantioselective variants may be achievable. Thus, the O'Donnell group has successfully performed allylic substitution upon imine-protected glycine α -acetates, using a BINAP ligand as the source of chirality and potassium malonate as the nucleophile (Scheme 4).^{26b}

Petasis has disclosed a nicely convergent, three component Mannich reaction which produces an allylic amine from the reaction of an alkenyl boronate with an amine and an aldehyde or electrophilic ketone. When glyoxylic acid is condensed with boronate **13** through the agency of L-phenylglycinol, protected D- α -cinnamylglycine is obtained in excellent ee. (Scheme 5).²⁷

All of the approaches discussed heretofore involve disconnections at the $\text{C}_\alpha\text{-R}$ bond, wherein the unsaturated side chain is coupled with an electrophilic glycine equivalent. By contrast, Snapper and Hoveyda, target alkenylglycines by disconnecting at the $\text{C}_\alpha\text{-CO}_2\text{H}$ bond. They have optimized the Ti(IV)-mediated 1,2- addition of cyanide to α,β -unsaturated iminium ions. Screening a library of chiral peptidic ligands for titanium, they identified the catalyst derived from tripeptide **16** as particularly effective (Scheme 6).^{28,29}

II. Quaternary β,γ -Unsaturated AA's

There are fewer methods available for the stereocontrolled synthesis of quaternary β,γ -unsaturated AA's. These are more densely functionalized targets with the α -carbon directly bearing amino, carboxyl and alkenyl functional groups, in addition to the usual (and often functionalized) side chain R group itself. Among the earliest entries into this AA class is the work of Schöllkopf in which bis-lactim ether, **18**, serves as a chiral alanine enolate equivalent.³⁰ Here the chiral element is essentially an L-valine auxiliary built into **18**. Condensation with acetone or acetophenone proceeds with high 1,4-stereoiduction. Subsequent dehydration and methanolysis produces methyl esters of substituted L-vinylalanine derivatives (**20**).

Seebach's classic synthesis of higher vinyl AA's served as part and parcel of a programmatic thrust to establish the principle of "self-regeneration of stereocenters" [SRS; previously referred to as SRC or self-regeneration (or reproduction) of chirality] in

asymmetric synthesis. In this case, the α -stereocenter originally present in methionine is used to induce a second stereocenter at the N,X-acetal carbon in a cyclic oxazolidinone or imidazolidinone derivative (Scheme 8). Upon subsequent generation of the enolate, the α -stereocenter is temporarily removed, and then reinstalled via alkylative introduction of the side chain. The (methyl)thioethyl methionine side chain is used to install the requisite unsaturation, via oxidation and pyrolysis, either before or after the alkylation event. This chemistry has been used to access enantiomerically enriched α -vinyl AA's bearing the alanine,^{31a} butyrine,^{31a} phenylalanine,^{31b} and tyrosine^{31c} side chains.

More recently, Hegedus and coworkers have combined their chromium carbene complex-mediated β -lactam synthesis with Ojima's diastereoselective lactam enolate alkylation methodology, resulting in a novel entry into α -vinylalanine (Scheme 9).³² Chiral β -lactam, **28**, may be regarded as a masked α -formylglycine equivalent. Alkylation of the potassium enolate thereof with methyl iodide proceeds with high diastereofacial selectivity. Unravelling of the formyl group, followed by methylenation and hydrolytic deprotection yields L- α -vinylalanine.

Very recently, Avenoz and Cativiela and their associates have reported an approach to α -vinylalanine that shares an "end game" methylenation with the Hegedus route.³³ However, in this case, the requisite α -formylalanine equivalent is generated by entirely different chemistry. Namely, absolute stereochemistry is set 8 via a Sharpless-Katsuki asymmetric epoxidation (SAE)³⁴ of allylic alcohol **31**. Imidate formation and 5-exo cyclization is then performed under Et₂AlCl-promotion according to the procedure of Hatakeyama.³⁵ The α -amino group is thereby installed with inversion of configuration. Protecting group interchange and Swern oxidation set the stage for Wittig methylenation, leading to the targeted quaternary β,γ -unsaturated amino acid.³⁶

As part of a program directed at developing new AADC inhibitors, we have been engaged in a multipronged approach toward quaternary, α -vinyl amino acids, with three principal synthetic aims: (i) control of absolute stereochemistry; (ii) introduction of biologically relevant AA side chains and (iii) transformation of the parent α -vinyl AA's into potential second generation inhibitor families (Scheme 2). Our initial approach was to formally α -vinylate an AA-derived dianion. These dianions are generated with two equivalents of base from N-benzoyl amino acid methyl esters. Ethylene oxide serves as an economical "vinyl cation equivalent" (Scheme 11).³⁷ α -Alkylation predominates and yields are improved in the presence of TMEDA. Interestingly, Michelle Pedersen (Morris) found that, in addition to simple alkyl side chains (i.e. Ala, Phe, Val), with appropriate protection, *heteroatom-functionalized* side chains (DOPA, Lys, His, Orn, HomoSer) may be carried into these dianions, without deleterious effects. Given that these alkylations proceed smoothly with a modest electrophile such as ethylene oxide, we expect this dianion chemistry to be of utility for the generation of other quaternary AA analogues.

The resulting α -substituted homoserine lactones **37** undergo selective ring opening at the alkyl carbon-oxygen bond with a new, non-reducing phenylselenolate equivalent developed in the work.^{37b} Oxidation and selenoxide pyrolysis then serves to install the α -vinyl group. At this stage, global deprotection (6 N HCl reflux) provides the racemic free, α -vinyl amino

acids. Alternatively, James Pumphrey, an undergraduate co-worker, noted that if one first reduces the esters to the corresponding N-benzoyl α -vinyl amino alcohols, one can partially resolve these by enzymatic acylation. Chemical deacylation of the enzymatic product then permits a second round of resolution. In this way, enantiomerically enriched L- α -vinylalanine and L- α -vinylphenylalanine may be obtained.³⁸

In light of the favorable reactivity of the aforementioned AA-derived dianions, it became attractive to investigate asymmetric versions of that chemistry. After all, it seemed likely that enolate geometry in these systems could be controlled via benzamidate nitrogen chelation to the enolate lithium. It would then remain only to control the facial selectivity of the alkylation reaction to achieve a high level of stereoselection. We envisioned doing so in an acyclic fashion, whereby the aryl π -system of an arylmenthyl type ester auxiliary would shield one face of the enolate. In fact, these goals were reduced to practice in the alkylation of the vinylglycine-derived dianionic dienolate **41**, which is outfitted with d'Angelo's 8-(β -naphthyl)menthyl auxiliary.³⁹ Our working model for the reactive conformation of this dienolate is provided in Scheme 12. Through the diligent work of Jill McFadden, it was established that the alkylation of **41** with appropriate electrophiles provides a convergent route to a range of important L- α -vinyl AA's, including the AADC inhibitors α -vinylornithine, α -vinyl-*m*-tyrosine and α -vinyllysine.⁴⁰ If desired, the chiral auxiliary may be recovered and recycled via a modification of Gassman's "anhydrous hydroxide" protocol for the cleavage of hindered esters.⁴¹

Parallel to this study, we had begun to explore a complementary approach to the targeted higher vinyl AA's, also emanating from vinylglycine (Scheme 13).⁴² Here, rather than recruit chiral information from an external auxiliary, the chiral information inherent at C $_{\alpha}$ in L-vinylglycine would be parlayed divergently into enantiomeric directing centers at C $_{\beta}$. An episelenonium ion-mediated 5-exo trig cyclization serves to mask the double bond and, in so doing, install the β -phenylselenomethyl directing group. Because the diastereomeric oxazolines **44t** and **44c** are separable by standard silica gel chromatography, yet yield mirror image enolates upon α -deprotonation, this may be regarded as a sort of *divergent* SRS approach. Oxazoline **44t** serves as a synthon for higher L- α -vinyl AA's, while **44c** conveniently provides an entry into the D-series.

Treatment of the alkylation products **45** with KOTBu effectively unmask the β,γ -unsaturation via eliminative oxazoline ring opening with release of an amidate leaving group. The resulting α -(2E-phenylseleno) vinyl AA's (**46**) are of interest in their own right, both from a chemical and spectroscopic (⁷⁷Se provides a potential NMR reporter group) point of view. However, they served here as the platform for the discovery of a new entry into vinyl stannanes. Namely, exposure of these vinyl selenides to trialkyltin radical leads to an efficient substitution reaction. A set of heretofore unexplored,⁴³ α -(2E-trialkylstannyl)vinyl AA's (**47**) results, and these may be obtained in high ee, and in either enantiomeric form, as desired. This simple substitution reaction had not been seen before and certainly merits further investigation. However, it is our purpose here to explore the chain extension chemistry of this novel class of quaternary, γ -stannyl- β,γ -unsaturated AA's.

44

If desired, protodestannylation may be carried out upon vinylstannanes **47**, concomitant with global acidolytic deprotection (Scheme 13), to provide the parent α -vinyl AA's. Alternatively, one can exploit the γ -stannyl group to position-specifically introduce a deuterium label by employing aqueous DCl (Scheme 14). In the case of L- α -(2E-tributylstannyl)vinylphenylalanine, this transformation proceeds cleanly and stereospecifically, with retention of configuration, as expected. Presumably, the same approach would provide a valuable means to introduce a tritium label into members of this AADC suicide substrate family for enzyme labeling studies.

The same stannylvinyl AA, **L-47a**, was used to explore the possibility for extending the α -branch via Pd⁰-mediated couplings of the Stille variety.⁴⁵ As is illustrated in Scheme 15, no significant complications were encountered with these quaternary AA scaffolds. Successful chain extensions were achieved with a range of electrophiles, from an aryl halide, to an acid chloride, to allylic and benzylic halides. In the latter case, the (Ph₃P)₂CIPd⁰Bn complex, originally reported by Stille for couplings with benzylic substrates,⁴⁶ also proved successful here.

We were also pleased to find that the α -(2E-stannyl)vinyl branch in these densely functionalized AA's may be conveniently transformed into an α -(2E-iodo)vinyl branch,⁴⁷ in nearly quantitative yield, upon treatment with I₂ (Scheme 16). This permitted us to explore transition metal catalyzed chain extension reactions of the opposite sense of polarity. That is, rather than enter the catalytic cycle "late" at the stage of the transmetalation, these new β,γ -unsaturated amino acids presumably enter the cycle "early" via oxidative addition to a PdL₂ or [PdL₂X]⁻ species.⁴⁸

Pleasingly, protected α -(2E-iodo)vinyl amino acids, **53**, derived from L- and D-phenylalanine and D-serine could be successfully deployed in such Pd⁰-mediated C-C bond-forming reactions (Scheme 17). Employing vinyltributylstannane with **L-53a**, and Pd₂dba₃ as Pd⁰ source, one obtains **54**, in which a 1,3-butadienyl branch now formally replaces the α -proton. Such quaternary amino acids hold potential as substrates for [4 π +2 π]-cycloadditions (vide infra). Alternatively, subjecting the antipode **D-53a** to a Negishi-type reaction⁴⁹ with a 1-styrenylzinc reagent derived from Rieke Zn*⁵⁰ leads to efficient cross-coupling. Given the variety of organozinc reagents available, and the functional group tolerance of such reagents, this opens up an important new manifold for chain extension. Finally, using the iodovinyl AA derived from D-serine (**D-53c**), good results were also obtained for an sp-sp² coupling of the Sonagashira variety.⁵¹

In a demonstration of proof of principle, the dienyl-AA **54** successfully participated in a Diels-Alder reaction with dimethyl acetylenedicarboxylate (DMAD) as dienophile (Scheme 18). There is particular significance to this result as this cycloaddition is expected to proceed via a sterically demanding transition state. Namely, two C-C bonds are formed along the α -branch, and one of these forms directly adjacent to the quaternary α -center. A bromine addition/HBr elimination sequence then allows one to aromatize the newly formed 6-membered ring. Overall, this chemistry provides a route into an interesting family of quaternary, arylglycine derivatives bearing the natural AA side chains.

Lastly, as a streamlined alternative to the Sonagashira route for the construction of γ,δ -sp²-sp bond, we have been able to apply of Shen's recently reported variant⁵² of the Stille reaction to this system. In this reaction, 1,1-dibromoalkenes couple with alkenylstannanes, to give enynes, particularly in polar solvents and in the presence of electron rich ligands. Under these conditions, the quaternary, α -(2E-stannyl)vinyl AA, **D-47a**, couples with geminal dibromomethylene partner **59** to yield directly the functional equivalent of a Sonagashira product (**60**), without the need to synthesize the iodovinyl AA.

CONCLUSIONS

A divergent SRS-type approach to protected, D- or L- quaternary, α -(2-stannyl)vinyl AA's has been developed. The enantiomeric purity of the starting L-vinylglycine is preserved through a sequence that involves:

- i. installation of a directing β -stereocenter via an episelenonium ion mediated alkene-masking step,
- ii. chromatographic separation of the diastereomeric D- and L-vinyl AA synthons, **44c** and **44t**,
- iii. enolate generation with KHMDS and alkylative side chain introduction with nearly absolute 1,2-stereoiduction,
- iv. oxazoline opening/alkene unmasking under classical E2-type conditions to produce a family of α -(2Ephenylseleno) vinyl AA's and
- v. direct transformation of the α -(2E-phenylseleno)vinyl α -branch to an α -(2E-tributylstannyl)vinyl branch via treatment with tributyltin radical.

The α -(2E-stannyl)vinyl AA's (or their iodovinyl derivatives), in turn, are shown to effectively participate in transition metal-mediated cross couplings of the Stille, Negishi, Sonagashira and Shen varieties. The AA products of these chain extension reactions bear a β,γ -unsaturated α -branch, in addition to the usual α -amino, α -carboxyl and side chain functional groups. Thus, the title stannylvinyl AA's serve as convenient building blocks for a wide range of scalemic, sterically congested amino acids, of either D- or L-handedness, that would otherwise be difficult to obtain.

EXPERIMENTAL

General

All reactions were conducted under an argon atmosphere using flame-dried glassware unless otherwise noted. Toluene, THF, and Et₂O were distilled from sodium benzophenone ketyl. HMPA and DMF were distilled from Na, in vacuo. Methylene chloride was distilled from CaH₂. NMR spectra were recorded on a Bruker-DRX-Avance-500 or a GE Omega-300 instrument. Chemical shifts are reported relative to residual CHCl₃ (7.25 ppm, ¹H; 77.0 ppm, ¹³C). Infrared spectra were obtained using a Nicolet Avatar 360 FTIR spectrometer. High resolution mass spectra were acquired at the Nebraska Center for Mass Spectrometry (University of Nebraska).

**(4S,5S)-4-Methoxycarbonyl-5-(phenylseleno)methyl-2-phenyloxazoline (44t)/
(4S,5R)-4-Methoxycarbonyl-5-(phenylseleno)methyl-2-phenyloxazoline (44c)**—To a solution of phenylselenenyl chloride (1.92 g, 10.0 mmol) in THF (40 mL) at -78°C was added silver triflate (2.82 g, 10.9 mmol) in THF (30 mL). The resulting orange mixture was stirred at -78°C for 20 minutes and then cooled to -100°C [EtOH- $\text{N}_2(\text{l})$ slush bath]. A solution of **L-43**^{24c} (2.00 g, 9.12 mmol) in THF (20 mL) at -100°C was then added via cannula and the reaction stirred for 2 h. EtOAc (60 mL) was added and the mixture was extracted with H_2O (3×80 mL). The organic layer was dried (MgSO_4), filtered, evaporated. Chromatography [PhCH_3 or $\text{PhH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (4:4:1)] provided trans-oxazoline (**44t**) (1.42 g, 42%) in a first fraction, and then cis-oxazoline (**44c**) (1.28 g, 37%). For **44t**: $[\alpha]_{\text{D}}^{24} +50.3$ (c 0.5, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 3.17 (dd, $J = 7, 13$ Hz, 1 H), 3.29 (dd, $J = 7, 13$ Hz, 1 H), 3.79 (s, 3 H), 4.71 (d, $J = 7$ Hz, 1 H), 5.12 (app dt, $J = 5, 7$ Hz, 1 H), 7.24 (m, 3 H), 7.36 (m, 2 H), 7.47 (m, 1 H), 7.56 (m, 2 H), 7.86 (d, $J = 8$ Hz, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 31.6, 52.6, 73.7, 81.3, 126.9, 127.6, 128.2, 128.6, 128.7, 129.2, 131.8, 133.7, 165.3, 171.1; IR (ATR) 1743, 1643 cm^{-1} . Anal. Calcd. for $\text{C}_{18}\text{H}_{17}\text{NO}_3\text{Se}$: C, 57.76, H, 4.58; N, 3.74. Found: C, 57.57; H, 4.22; N, 3.93. For **44c**: $[\alpha]_{\text{D}}^{24} +16.2$ (c 0.6, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 3.16 (dd, $J = 5.5, 13$ Hz, 1 H), 3.24 (dd, $J = 8, 13$ Hz, 1 H), 3.77 (s, 3 H), 5.02 (d, $J = 10$ Hz, 1 H), 5.09 (ddd, $J = 5.5, 8, 10$ Hz, 1 H), 7.24 (m, 3 H), 7.36 (m, 2 H), 7.47 (m, 1 H), 7.56 (m, 2 H), 7.88 (d, $J = 8$ Hz, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 27.4, 52.4, 71.2 (CH), 81.0, 126.7, 127.6, 128.3, 128.6, 129.0, 129.2, 132.0, 133.5, 165.9, 170.1; IR (ATR) 1740, 1643 cm^{-1} . Anal. Calcd. for $\text{C}_{18}\text{H}_{17}\text{NO}_3\text{Se}$: C, 57.76; H, 4.58; N, 3.74. Found: C, 57.88; H, 4.42; N, 3.98.

General Procedure A

(4R,5S)-4-Benzyl-4-methoxycarbonyl-5-(phenylseleno)methyl-2-phenyloxazoline (L-45a)—To a solution of KHMDS (7.0 mL, 0.5 M in toluene) and HMPA (3.0 mL) in THF (3.0 mL) at -78°C was added **44t** (98% ee, Chiralcel OD) (1.20 g, 3.20 mmol) in THF (10 mL) at -78°C via cannula. The resulting deep orange/red solution was stirred for 20 min at -78°C followed by addition of benzyl bromide (0.45 mL, $d = 1.44$, 3.80 mmol). After stirring for 3 h, the reaction mixture was poured into ether (15 mL) and NH_4Cl (aqueous, 15 mL). Following further extraction with EtOAc (3×15 mL), the combined organics were dried (MgSO_4), filtered, evaporated, and chromatographed (10% EtOAc/hexanes) to give **L-45a** (1.34 g, 90%, 98% ee, Chiralcel OD) as a white solid: mp $79\text{--}81^{\circ}\text{C}$; $[\alpha]_{\text{D}}^{24} +48.5$ (c 1.0, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 3.21–3.24 (m, 3 H), 3.49 (d, $J = 13.7$ Hz, 1 H), 3.84 (s, 3 H), 4.89 (t, $J = 6.6$ Hz, 1 H), 7.23–7.34 (m, 5 H), 7.36–7.38 (m, 3 H), 7.44 (t, $J = 7.7$ Hz, 2 H), 7.55 (t, $J = 7.5$ Hz, 1 H), 7.62–7.64 (m, 2 H), 7.88 (d, $J = 7.3$ Hz, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 28.3, 44.3, 52.6, 81.1, 84.8, 126.8, 127.0, 127.4, 128.0, 128.2, 128.5, 129.2, 129.3, 130.9, 131.7, 133.6, 134.9, 164.2, 171.7. Anal. Calcd. For $\text{C}_{25}\text{H}_{23}\text{NO}_3\text{Se}$: C, 64.66; H, 4.99; N, 3.02. Found: C, 64.98; H, 4.58; N, 3.03.

(4S,5R)-4-Benzyl-4-methoxycarbonyl-5-(phenylseleno)methyl-2-phenyloxazoline (D-45a)—From **44c** (>99% ee, Chiralcel OD) (1.00 g, 2.67 mmol) and benzyl bromide (0.40 mL, $d = 1.44$, 3.20 mmol) following General Procedure A, was obtained **D-45a** (0.99 g, 80%, >99% ee, Chiralcel OD): $[\alpha]_{\text{D}}^{24} -51.1$ (c 1.0, CHCl_3); ^1H

NMR (500 MHz, CDCl₃) δ 3.21–3.25 (m, 3 H), 3.49 (d, J = 13.7 Hz, 1 H), 3.84 (s, 3 H), 4.89 (t, J = 6.6 Hz, 1 H), 7.23–7.34 (m, 5 H), 7.36–7.38 (m, 3 H), 7.44 (t, J = 7.7 Hz, 2 H), 7.55 (t, J = 7.5 Hz, 1 H), 7.62–7.64 (m, 2 H), 7.88 (d, J = 7.3 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 28.4, 44.3, 52.6, 81.1, 84.8, 126.9, 127.5, 128.0, 128.2, 128.6, 129.2, 129.4, 130.9, 131.7, 133.4, 134.9, 142.0, 164.3, 171.7; IR (ATR) 3012, 1747, 1659 cm⁻¹.

(4S,5R)-4-(Benzyloxy)methyl-4-methoxycarbonyl-5-(phenylseleno)methyl-2-phenyloxazoline (D-45c)—From **44c** (>99% ee, Chiralcel OD) (1.00 g, 2.67 mmol) and benzyloxymethyl bromide (0.64 g, 3.20 mmol), following General Procedure A, was obtained **D-45c** (1.20 g, 90%, >99% ee, Chiralcel OD) as an oil, after flash chromatography (25% EtOAc/hexanes): $[\alpha]_D^{24}$ -36.5 (c 1.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 3.17 (dd, J = 4.5, 8.5 Hz, 1 H), 3.26 (dd, J = 4, 8.5 Hz, 1 H), 3.77 (s, 3 H), 3.85 (d, J = 9.9 Hz, 1 H), 3.89 (d, J = 9.9 Hz, 1 H), 4.58 (s, 2 H), 5.00 (dd, J = 4.5, 8.8 Hz, 1 H), 7.23–7.28 (m, 7 H), 7.37–7.40 (m, 3 H), 7.48 (t, J = 7.3, 1 H), 7.56–7.57 (m, 2 H), 7.89 (d, J = 7.4 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃) δ 28.2, 52.6, 73.2, 73.7, 80.9, 83.5, 126.9, 127.3, 127.6, 127.7, 128.2, 128.3, 128.6, 128.7, 129.1, 129.2, 129.5, 131.7, 133.1, 137.8, 165.2, 170.3; IR (ATR) 1734, 1652, 1450 cm⁻¹; MS (FAB, 3-NBA), 518 (100, M+Na); HRMS (FAB, 3-NBA) m/z calcd for C₂₆H₂₅NO₄Se (M+Na) 518.0846, obsd 518.0839 (Δ = +1.4).

General Procedure B

Methyl N-Benzoyl-L- α -(2E-phenylseleno)vinylphenylalaninate (L-46a)—To a solution of **L-45a** (79 mg, 0.17 mmol) at 0 °C in DMF (2.3 mL) was added KOtBu (38 mg, 0.34 mmol). After warming to rt and stirring for 2 h, the resulting solution was poured into EtOAc (15 mL) and 1 N HCl (15 mL). Following a second extraction with EtOAc (10 mL), the combined organics were dried (MgSO₄), filtered, and evaporated. The crude product was taken up in ether (10 mL) and treated with diazomethane. Evaporation of the solvent and flash chromatography (25% EtOAc/hexanes) yielded **L-46a** (60 mg, 76%): $[\alpha]_D^{24}$ +21.4 (c 0.1, CDCl₃); ¹H NMR (500 MHz, CDCl₃) δ 3.40 (d, J = 13 Hz, 1 H), 3.82 (s, 3 H), 3.91 (d, J = 13 Hz, 1 H), 6.29 (d, J = 16 Hz, 1 H), 6.70 (d, J = 16 Hz, 1 H), 6.97 (s, 1 H), 7.05 m, 2 H), 7.22 (m, 3 H), 7.27 (m, 3 H), 7.39 (t, J = 7.5 Hz, 2 H), 7.47 (m, 3 H), 7.68 (d, J = 7.5 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 40.3, 53.1, 66.5, 121.5, 126.9, 127.1, 127.3, 128.3, 128.4, 128.6, 129.3, 129.9, 131.6, 132.3, 133.3, 134.7, 135.4, 166.3, 171.7; IR (ATR) 1736, 1650 cm⁻¹. Anal. Calcd for C₂₅H₂₃NO₃Se: C, 64.66; H, 4.99; N, 3.02. Found: C, 64.86; H, 5.30; N, 2.92.

Methyl N-Benzoyl-D- α -(2E-phenylseleno)vinylphenylalaninate (D-46a)—From **D-45a** (0.51 g, 1.1 mmol) in DMF (6 mL), following General Procedure B, was obtained **D-46a** (357 mg, 70%) as an oil after diazomethane esterification and flash chromatography (30% EtOAc/hexanes): $[\alpha]_D^{24}$ -20.4 (c 0.3, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 3.40 (d, J = 13 Hz, 1 H), 3.82 (s, 3 H), 3.91 (d, J = 13 Hz, 1 H), 6.29 (d, J = 16 Hz, 1 H), 6.70 (d, J = 16 Hz, 1 H), 6.97 (s, 1 H), 7.05 m, 2 H), 7.22 (m, 3 H), 7.27 (m, 3 H), 7.39 (t, J = 7.5 Hz, 2 H), 7.47 (m, 3 H), 7.68 (d, J = 7.5 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 40.3, 53.1, 66.5, 121.5, 126.9, 127.1, 127.3, 128.3, 128.4, 128.6, 129.3, 129.9, 131.6, 132.3, 133.3, 134.7, 135.4, 166.3, 171.7; IR (ATR) 1736, 1677 cm⁻¹; MS (FAB, 3-NBA) 466 (M+H, 100);

HRMS (FAB, 3-NBA) m/z calcd for $C_{25}H_{23}NO_3Se$ (M+H) 466.0921, obsd 466.0907 (= +3.1 ppm).

Methyl N-Benzoyl-O-benzyl-D- α -(2E-phenylseleno)vinylserinate (D-46c)—From **D-45c** (1.2 g, 2.42 mmol) in THF (30 mL), following General Procedure B, was obtained **D-46c** (900 mg, 75%) after diazomethane esterification and flash chromatography (25% EtOAc/hexanes): $[\alpha]_D^{24} +20.4$ (c 2.0, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 3.82 (s, 3 H), 3.99 (d, J = 9.3 Hz, 1 H), 4.30 (d, J = 9.3 Hz, 1 H), 4.48 (d, J = 12.3 Hz, 1 H), 4.55 (d, J = 12.3 Hz, 1 H), 6.23 (d, J = 15.6 Hz, 1 H), 6.79 (d, J = 15.6 Hz, 1 H), 7.23–7.32 (m, 9 H), 7.46–7.48 (m, 4 H), 4.52 (m, 1 H), 7.84 (d, J = 7.5 Hz; 2 H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 53.2, 65.9, 70.7, 73.4, 122.6, 127.0, 127.2, 127.6, 127.8, 128.3, 128.5, 129.3, 129.8, 130.0, 131.7, 132.2, 134.2, 137.6, 166.3, 170.7; IR (ATR) 3018, 1747, 1665 cm^{-1} ; MS (FAB, 3-NBA) 502 (100, M+Li); HRMS (FAB, 3-NBA) m/z calcd for $C_{26}H_{25}NO_4Se$ (M+Li) 502.1109, obsd 502.1100 (= +1.7 ppm).

General Procedure C

Methyl N-Benzoyl-D- α -(2E-tri-n-butylstannyl)vinylphenylalanine (D-47a)—To a deoxygenated solution of **D-46a** (0.52 g, 1.12 mmol) in toluene (15 mL) was added AIBN (42 mg, 0.26 mmol) and tributyltin hydride (0.58 mL, 2.24 mmol). The solution was then stirred at 85 °C for 1.5 h. After cooling the reaction mixture to rt, EtOAc (50 mL) and H_2O (50 mL) were added. After further extraction with EtOAc (3 $\times$ 50 mL), the combined organics were dried ($MgSO_4$), filtered, evaporated, and chromatographed (0–10% EtOAc/hexanes) to give **D-47a** (0.53 g, 80%): $[\alpha]_D^{24} -15.7$ (c 1.0, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 0.84–0.95 (m, 15 H), 1.25–1.34 (m, 6 H), 1.45–1.56 (m, 6 H), 3.55 (d, J = 13 Hz, 1 H), 3.80 (s, 3 H), 3.82 (d, J = 13 Hz, 1 H), 6.16 (d, J = 19.2 Hz, 1 H), 6.23 (d, J = 19.2 Hz, 1 H), 6.82 (s, 1 H), 7.07–7.11 (m, 2 H), 7.18–7.20 (m, 3 H), 7.42 (t, J = 7.3 Hz, 2 H), 7.48 (t, J = 7.3 Hz, 1 H), 7.71 (d, J = 7.3 Hz, 2 H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 9.6, 13.7, 27.2, 28.9, 33.7, 52.8, 67.4, 126.8, 126.9, 128.1, 128.5, 130.1, 130.3, 131.4, 135.0, 136.3, 143.9, 166.3, 172.3; IR (ATR) 1737, 1483 cm^{-1} ; HREI, calcd for $C_{31}H_{45}NO_3Sn$ (M-t-butyl) 542.1717, obsd 542.1709 (= +1.5).

Methyl N-Benzoyl-L- α -(2E-tri-n-butylstannyl)vinylphenylalanine (L-47a)—From **L-46a** (45 mg, 0.10 mmol) in toluene (1.3 mL), following General Procedure C, was obtained **L-47a** (48 mg, 84%), after flash chromatography (20% EtOAc/hexanes): $[\alpha]_D^{24} +14.3$ (c 1.8, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 0.84–0.98 (m, 15 H), 1.25–1.33 (m, 6 H), 1.45–1.56 (m, 6 H), 3.55 (d, J = 13 Hz, 1 H), 3.79 (s, 3 H), 3.80 (d, J = 13 Hz, 1 H), 6.16 (d, J = 19.2 Hz, 1 H), 6.23 (d, J = 19.2 Hz, 1 H), 6.80 (s, 1 H), 7.07–7.17 (m, 2 H), 7.18–7.20 (m, 3 H), 7.42 (t, J = 7.3 Hz, 2 H), 7.48 (t, J = 7.3 Hz, 1 H), 7.71 (d, J = 7.3 Hz, 2 H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 9.6, 13.7, 27.2, 28.9, 33.7, 52.8, 67.4, 126.8, 126.9, 128.1, 128.5, 130.1, 130.3, 131.4, 135.0, 136.3, 143.9, 166.3, 172.3; IR (ATR) 1738, 1482 cm^{-1} . Anal. Calcd for $C_{31}H_{45}NO_3Sn$: C, 62.22; H, 7.58; N, 2.34. Found: C, 62.40; H, 7.32; N, 2.28.

Methyl N-Benzoyl-O-benzyl-D- α -(2E-tri-n-butylstannyl)vinylserinate (D-47c)—From **D-46c** (800 mg, 1.6 mmol), following General Procedure C, was obtained **D-47c** (748

mg, 74%) after flash chromatography (20% EtOAc/hexanes): $[\alpha]_{\text{D}}^{24} +24.4$ (c 0.8, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 0.84–0.93 (m, 15 H), 1.24–1.32 (m, 6 H), 1.45–1.50 (m, 6 H), 3.78 (s, 3 H), 4.06 (d, J = 9.3 Hz, 1 H), 4.33 (d, J = 9.3 Hz, 1 H), 4.49 (d, J = 12 Hz, 1 H), 4.56 (d, J = 12 Hz, 1 H), 6.09 (d, J = 19.3 Hz, 1 H), 6.36 (d, J = 19.3 Hz, 1 H), 7.18 (s, 1 H), 7.24–7.32 (m, 5 H), 7.47 (t, J = 7.5 Hz, 2 H), 7.52 (t, J = 7.5 Hz, 1 H), 7.48 (d, J = 7.5 Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 9.6, 13.6, 27.1, 28.9, 52.9, 67.2, 70.9, 73.3, 17.1, 127.5, 127.6, 128.3, 128.5, 131.4, 131.6, 134.8, 138.0, 141.0, 166.1, 171.4; IR (ATR) 1735, 1443 cm^{-1} ; MS (FAB, 3-NBA), 636 (100, $\text{M}+\text{Li}$); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{32}\text{H}_{47}\text{NO}_4\text{Sn}$ ($\text{M}+\text{Li}$) 636.2687, obsd 636.2698 (δ = –1.8 ppm).

(2'-E-Deuterio)-L- α -vinylphenylalanine (L-48a)—A solution of **L-47a** (46 mg, 0.08 mmol) in 6 N DCl (1.0 mL) was stirred at light reflux for 4.5 h. Then the solution was cooled, taken up in H_2O (5 mL) and extracted with CH_2Cl_2 (2×5.5 mL). The residue was applied to a Dowex 50 $\times$ 8 ion-exchange column. After the column was washed with H_2O , elution with 1.3 M NH_4OH afforded 2'-deuterio **L-48a** (11.3 mg, 75%): $[\alpha]_{\text{D}}^{24} -6.6$ (c 0.3, D_2O); ^1H NMR (300 MHz, D_2O) δ 3.10 (d, J = 14.3 Hz, 1 H), 3.43 (d, J = 14.3 Hz, 1 H), 5.30 (d, J = 17.9 Hz, 1 H), 6.19 (d, J = 17.7 Hz, 1 H), 7.28 (m, 2 H), 7.38 (m, 3 H); ^{13}C NMR (75 MHz, D_2O) δ 42.1, 66.9, 117.4, 128.8, 129.7, 130.9, 134.4, 135.8, 174.4; MS (FAB, 3-NBA) 193 (69, $\text{M}+1$), 219 (100); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{11}\text{H}_{12}\text{NO}_2\text{D}$ ($\text{M}+1$) 193.1087, obsd 193.1085 (δ = +1.1 ppm).

Methyl N-Benzoyl- α -1-[(4'-nitro)-E-styrenyl]-L-phenylalaninate (49)—A solution of $\text{Pd}_2(\text{dba})_3$ (14 mg, 0.02 mmol) and 1-iodo-4-nitrobenzene (21.0 mg, 0.09 mmol) in THF (1.0 mL) was stirred for 10 min at rt. Then **L-47a** (50.0 mg, 0.09 mmol) in THF (1.0 mL) was added via cannula. The reaction was stirred at 50 $^\circ\text{C}$ for 2 h, then cooled to rt. Ethyl acetate (4 mL) was added and the mixture was filtered through Celite. The solvent was evaporated off and the crude product was chromatographed (10–30% EtOAc/hexanes) to give **49** (30.6 mg, 85%): $[\alpha]_{\text{D}}^{24} +71.8$ (c 0.6, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 3.49 (d, J = 13 Hz, 1 H), 3.88 (s, 3 H), 4.02 (d, J = 13 Hz, 1 H), 6.64 (d, J = 16 Hz, 1 H), 6.78 (d, J = 16 Hz, 1 H), 7.09 (m, 2 H), 7.17 (s, 1 H), 7.24 (m, 3 H), 7.45 (app t, J = 7.6 Hz, 2 H), 7.54 (m, 3 H), 7.76 (d, J = 7.2 Hz, 2 H), 8.18 (d, J = 8.8 Hz, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 40.8, 53.3, 65.6, 123.9, 126.9, 127.3, 127.4, 128.5, 128.7, 128.9, 129.9, 131.9, 132.9, 135.1, 142.7, 143.3, 147.2, 166.3, 171.8; IR (ATR) 3020, 1740, 1653, 1515, 1483, 1342 cm^{-1} ; MS (FAB, 3-NBA) 431 (100, $\text{M}+1$); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_5$ ($\text{M}+1$) 431.1607, obsd 431.1613 (δ = –1.4 ppm).

Methyl N-Benzoyl- α -(2E-benzoyl)vinyl-D-phenylalaninate (50)—To a solution of **D-47a** (20 mg, 0.05 mmol) and $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (7 mg, 0.01 mmol) in THF (0.5 mL) was added benzoyl chloride (6 μL , 0.05 mmol). The reaction mixture was refluxed for 3 h, cooled to rt, poured into EtOAc (0.5 mL) and extracted with H_2O (2×0.5 mL). The organic layer was dried (MgSO_4), filtered, evaporated and chromatographed (30% EtOAc/hexanes) to give **50** (8 mg, 60%) as an oil. $[\alpha]_{\text{D}}^{24} -26.3$ (c 0.4, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 3.48 (d, J = 13.4 Hz, 1 H), 3.84 (s, 3 H), 3.94 (d, J = 13.4 Hz, 1 H), 7.00 (d, J = 16.0 Hz, 1 H), 7.10–7.13 (m, 3 H), 7.22 (d, J = 16.0 Hz, 1 H), 7.25–7.28 (m, 3 H), 7.44–7.50 (m, 4 H), 7.56 (app t, J = 7.6 Hz, 2 H), 7.75 (d, J = 7.2 Hz, 2 H), 7.90 (d, J = 7.2 Hz, 2 H); ^{13}C NMR

(75 MHz, CDCl₃) δ 40.4, 53.5, 65.6, 126.5, 127.0, 127.5, 128.5, 128.6, 128.7, 128.8, 129.8, 131.9, 133.0, 134.8, 144.7, 166.4, 171.2; IR (ATR) 2993, 1734, 1659, 1634, 1508 cm⁻¹; MS (FAB, 3-NBA) 414 (100, M+1); HRMS (FAB, 3-NBA) *m/z* calcd for C₂₆H₂₃NO₄ (M+1) 414.1705, obsd 414.1718 (= -3.0 ppm).

Methyl N-Benzoyl-α-1-(E-1,4-pentadienyl)-D-phenylalaninate (51)—To a solution of (PPh₃)₂Pd(PhCH₂)Cl (1.1 mg, 1.5 μmol) in THF (0.4 mL) was added allyl bromide (4 μL, 0.05 mmol) and **D-47a** (30 mg, 0.05 mmol). The reaction mixture was stirred at reflux for 3 h. After cooling to rt, EtOAc (5 mL) was added and the mixture was filtered through Celite, evaporated and chromatographed (10% EtOAc/hexanes) to give **51** (15 mg, 84%) as an oil: [α]_D²⁴ -33.2 (c 1.1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 2.86 (t, *J* = 6.4 Hz, 2 H), 3.44 (d, *J* = 13.5 Hz, 1 H), 3.84 (s, 3 H), 3.89 (d, *J* = 13.5 Hz, 1 H), 5.04 (br d, *J* = 10.5 Hz, 1 H), 5.06 (br d, *J* = 17 Hz, 1 H), 5.72 (dt, *J* = 6, 16 Hz, 1 H), 5.85 (d, *J* = 16 Hz, 1 H), 5.80–5.90 (m, 1 H), 6.96 (s, 1 H), 7.08–7.11 (m, 2 H), 7.19–7.27 (m, 3 H), 7.43 (app t, *J* = 7.4 Hz, 2 H), 7.51 (app t, *J* = 7.4 Hz, 1 H), 7.72 (d, *J* = 7.0 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃) δ 36.1, 40.2, 52.9, 65.3, 115.9, 126.9, 127.0, 128.2, 128.6, 129.4, 129.9, 130.0, 134.9, 135.8, 135.9, 166.3, 172.6; IR (ATR) 3031, 1747, 1671, 1514, 1483 cm⁻¹; MS (FAB, 3-NBA) 350 (100, M+1); HRMS (FAB, 3-NBA) *m/z* calcd for C₂₂H₂₃NO₃ (M+1) 350.1756, obsd 350.1759 (= +0.8 ppm).

Methyl N-Benzoyl-α-1-[E-(3-phenyl)propenyl]-D-phenylalaninate (52)—To a solution of (PPh₃)₂Pd(PhCH₂)Cl (6 mg, 8 μmol) and benzyl bromide (10.5 mg, 0.06 mmol) in THF (1 mL) was added **D-47a** (30 mg, 0.05 mmol). The solution was refluxed for 3 h, cooled to rt, and H₂O (5 mL) was added. The mixture was extracted with EtOAc (2 × 5 mL). The organics were combined, dried (MgSO₄), filtered, evaporated and chromatographed (0–10% EtOAc/hexanes) to give **52** (13 mg, 63%) as an oil: [α]_D²⁴ -47.8 (c 0.7, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 3.46 (d, *J* = 13.4 Hz, 1 H), 3.47 (d, *J* = 6.2 Hz, 2 H), 3.84 (s, 3 H), 3.96 (d, *J* = 13.4 Hz, 1 H), 5.85 (dt, *J* = 6, 16 Hz, 1 H), 5.94 (d, *J* = 16 Hz, 1 H), 6.96 (s, 1 H), 7.07–7.10 (m, 2 H), 7.17–7.24 (m, 6 H), 7.27–7.33 (m, 2 H), 7.42 (app t, *J* = 7.2 Hz, 2 H), 7.51 (app t, *J* = 7.2 Hz, 1 H), 7.72 (d, *J* = 7.0 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃) δ 38.4, 40.3, 65.1, 126.2, 126.8, 126.9, 128.2, 128.4, 128.6, 130.0, 130.1, 130.7, 131.5, 134.8, 135.9, 139.6, 166.3, 172.6; IR (ATR) 3018, 1741, 1671, 1527, 1482 cm⁻¹; MS (FAB, 3-NBA) 400 (100, M+1); HRMS (FAB, 3-NBA) *m/z* calcd for C₂₆H₂₅NO₃ (M+1) 400.1894, obsd 400.1895 (= -0.1 ppm).

General Procedure D

Methyl N-Benzoyl-α-(2E-iodo)vinyl-L-phenylalaninate (L-53a)—To a solution of **L-47a** (150 mg, 0.26 mmol) in CCl₄ (4.4 mL) at 4 °C was added iodine (167 mg, 0.66 mmol). The mixture was stirred at 4 °C for 30 min. Sodium bisulfite (10% aqueous) was added and the solution was extracted with ether (2 × 5 mL). The organics were combined, dried (MgSO₄), filtered, evaporated and chromatographed (10% EtOAc/hexanes) to give **L-53a** (100 mg, 92%): [α]_D²⁴ +52.7 (c 0.7, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 3.35 (d, *J* = 13.6 Hz, 1 H), 3.86 (s, 3 H), 3.92 (d, *J* = 13.6 Hz, 1 H), 6.46 (d, *J* = 14.8 Hz, 1 H), 6.92 (d, *J* = 14.8 Hz, 1 H), 7.02 (s, 1 H), 7.07 (m, 2 H), 7.24 (m, 3 H), 7.44 (app t, *J* = 7.4 Hz, 2 H), 7.52 (app t, *J* = 7.3 Hz, 1 H), 7.77 (d, *J* = 7.1 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃) δ

41.2, 54.3, 68.9, 80.2, 127.9, 128.4, 129.5, 129.7, 130.9, 132.8, 135.3, 135.8, 143.5, 167.3, 172.0; IR (ATR) 2949, 1735, 1653 cm^{-1} ; MS (FAB, 3-NBA) 436 (100, M+1); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{19}\text{H}_{18}\text{NO}_3\text{I}$ (M+1) 436.0410, obsd 436.0413 ($\delta = -0.8$ ppm).

Methyl N-Benzyl- α -(2E-iodo)vinyl-D-phenylalaninate (D-53a)—From **D-47c** (240 mg, 0.41 mmol), following General Procedure D, was obtained **D-53a** (160 mg, 90%) after flash chromatography (10% EtOAc/hexanes): $[\alpha]_{\text{D}}^{24} -50.0$ (c 0.5, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 3.35 (d, $J = 13.6$ Hz, 1 H), 3.86 (s, 3 H), 3.92 (d, $J = 13.6$ Hz, 1 H), 6.46 (d, $J = 14.8$ Hz, 1 H), 6.92 (d, $J = 14.8$ Hz, 1 H), 7.02 (s, 1 H), 7.07 (m, 2 H), 7.24 (m, 3 H), 7.44 (app t, $J = 7.4$ Hz, 2 H), 7.52 (app t, $J = 7.3$ Hz, 1 H), 7.77 (d, $J = 7.1$ Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 40.1, 53.3, 67.9, 79.3, 126.9, 127.4, 128.5, 128.7, 129.9, 131.8, 134.3, 134.8, 142.4, 167.3, 171.0; IR (ATR) 3031, 1753, 1671 cm^{-1} ; MS (FAB, 3-NBA) 436 (100, M+1); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{19}\text{H}_{18}\text{NO}_3\text{I}$ (M+1) 436.0410, obsd 436.0396 ($\delta = +3.2$ ppm).

Methyl N-Benzoyl-O-benzyl- α -(2E-iodo)vinyl-D-serinate (D-53c)—From **D-47a** (738 mg, 1.17 mmol), following General Procedure D, was obtained **D-53c** (540 mg, 98%) after flash chromatography (10% EtOAc/hexanes): $[\alpha]_{\text{D}}^{24} +24.7$ (c 0.6, CDCl_3); ^1H NMR (300 MHz, CDCl_3) δ 3.82 (s, 3 H), 3.91 (d, $J = 9.3$ Hz, 1 H), 4.22 (d, $J = 9.3$ Hz, 1 H), 4.50 (d, $J = 12.2$ Hz, 1 H), 4.58 (d, $J = 12.2$ Hz, 1 H), 6.52 (d, $J = 14.8$, 1 H), 6.81 (d, $J = 14.8$ Hz, 1 H), 7.24–7.33 (m, 6 H), 7.46 (app t, $J = 7.3$ Hz, 2 H), 7.55 (app t, $J = 7.3$ Hz, 1 H), 7.82 (d, $J = 7.4$ Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 53.4, 67.3, 70.4, 73.4, 80.3, 127.1, 127.7, 127.9, 127.5, 128.6, 131.9, 133.9, 137.3, 139.8, 166.3, 170.0; IR (ATR) 3018, 1747, 1671, 1514 cm^{-1} ; MS (FAB, 3-NBA) 472 (100, M+Li); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_4\text{I}$ (M+Li) 472.0597, obsd 472.0602 ($\delta = -0.9$ ppm).

Methyl N-Benzoyl- α -1-(E-1,3-butadienyl)-L-phenylalaninate (54)—To a solution of $\text{Pd}_2(\text{dba})_3$ (1.9 mg, 2.00 μmol) and tri-(2-furyl)phosphine (4.3 mg, 0.02 mmol) in THF (2 mL) was added **L-53a** (50 mg, 0.12 mmol). The mixture was stirred for 10 min at rt. Then tributyl(vinyl)tin (38.1 mg, 0.12 mmol) was added and the reaction mixture was stirred at 50 $^\circ\text{C}$ for 2 h, filtered through Celite and the solvent was evaporated. The crude product was chromatographed (10% EtOAc/hexanes) to yield **54** (24.9 mg, 65%): $[\alpha]_{\text{D}}^{24} +52.3$ (c 0.5, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 3.42 (d, $J = 13$ Hz, 1 H), 3.82 (s, 3 H), 3.92 (d, $J = 13$ Hz, 1 H), 5.15 (d, $J = 10$ Hz, 1 H), 5.21 (d, $J = 16.6$ Hz, 1 H), 6.04 (d, $J = 15.5$ Hz, 1 H), 6.24 (dd, $J = 15.4$ Hz, 1 H), 6.38 (dt, $J = 15.7$, 10 Hz, 1 H), 7.00 (s, 1 H), 7.07 (m, 2 H), 7.20 (m, 3 H), 7.40 (app t, $J = 7.6$ Hz, 2 H), 7.50 (app t, $J = 7.4$ Hz, 1 H), 7.71 (d, $J = 7.3$ Hz, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 40.3, 53.1, 65.3, 118.8, 126.9, 127.1, 128.3, 128.6, 129.9, 131.6, 131.8, 134.7, 135.7, 137.8, 142.0, 166.3, 172.3; IR (ATR) 3029, 1735, 1653 cm^{-1} ; MS (FAB, 3-NBA) 336 (100, M+1); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{21}\text{H}_{21}\text{NO}_3$ (M+1) 336.1600, obsd 336.1598 ($\delta = +0.4$ ppm).

Methyl N-Benzoyl- α -1-[(3-phenyl)-E-1,3-butadienyl]-D-phenylalaninate (55)—To a solution of **D-53a** (30 mg, 0.07 mmol) and $\text{Pd}_2(\text{dba})_3$ (11 mg, 14 μmol) in THF (0.6 mL) was added 1-phenylvinylzinc bromide [0.6 mL of a 0.5 M solution in THF (Rieke Metals, Inc.; Lincoln, Nebraska); 0.3 mmol]. The solution was then stirred at 40 $^\circ\text{C}$ for 8 h.

The reaction mixture was cooled and poured into NH_4Cl (5 mL) and extracted with EtOAc (2×5 mL). The combined organic layers were dried (MgSO_4), filtered, evaporated and chromatographed (10% EtOAc/hexanes) to give **55** (22 mg, 79%) as an oil: $[\alpha]_{\text{D}}^{24} -12.4$ (c 1.1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 3.46 (d, $J = 13.6$ Hz, 1 H), 3.84 (s, 3 H), 3.90 (d, $J = 13.6$ Hz, 1 H), 5.28 (d, $J = 16.9$ Hz, 2 H), 6.00 (d, $J = 16$ Hz, 1 H), 6.52 (d, $J = 16$ Hz, 1 H), 6.98 (s, 1 H), 7.07–7.09 (m, 2 H), 7.21–7.24 (m, 4 H), 7.33–7.39 (m, 4 H), 7.45 (app t, $J = 7.3$ Hz, 2 H), 7.53 (app t, $J = 7.3$ Hz, 1 H), 7.75 (d, $J = 7.3$ Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 40.3, 53.0, 65.3, 117.9, 126.9, 127.0, 127.6, 128.2, 128.3, 128.6, 130.0, 131.3, 131.6, 132.4, 134.8, 135.8, 139.7, 146.7, 166.3, 172.3; IR (ATR) 3043, 1741, 1671, 1508 cm^{-1} ; MS (FAB, 3-NBA) 434 ($\text{M}+\text{Na}$, 74); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{27}\text{H}_{25}\text{NO}_3$ ($\text{M}+\text{Na}$) 434.1711, obsd 434.1711 ($\delta = +0.7$).

Methyl N-Benzoyl-O-benzyl- α -1-(E-oct-1-en-3-ynyl)-D-serinate (56)—To a solution of **D-53a** (20 mg, 0.04 mmol) CuI (400 μg , 2 μmol) and $(\text{PPh}_3)_2\text{PdCl}_2$ (300 μg , 0.43 μmol) in diethylamine (0.5 mL) was added 1-hexyne (5 μL , $d = 0.715$, 0.04 mmol). The reaction mixture was stirred at rt for 2 h. The diethylamine was evaporated and H_2O (5 mL) was added to the residue. The mixture was extracted with EtOAc (2×5 mL). The combined organics were filtered through Celite, dried (MgSO_4), evaporated and chromatographed (10% EtOAc/hexanes) to yield **56** (15.7 mg, 87%) as an oil: $[\alpha]_{\text{D}}^{24} +23.8$ (c 0.8, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 0.90 (t, $J = 7.2$ Hz, 3 H), 1.36–1.51 (m, 4 H), 2.28 (t, $J = 7.0$ Hz, 2 H), 3.80 (s, 3 H), 3.93 (d, $J = 9.3$ Hz, 1 H), 4.27 (d, $J = 9.3$ Hz, 1 H), 4.48 (d, $J = 12.2$ Hz, 1 H), 4.58 (d, $J = 12.2$ Hz, 1 H), 5.76 (d, $J = 16.2$ Hz, 1 H), 6.24 (d, $J = 16.2$ Hz, 1 H), 7.22–7.31 (m, 6 H), 7.45 (app t, $J = 7.2$ Hz, 2 H), 7.51 (app t, $J = 7.2$ Hz, 1 H), 7.82 (d, $J = 7.2$ Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 13.5, 19.1, 21.9, 30.6, 53.3, 65.0, 70.8, 73.4, 93.3, 113.1, 127.1, 127.6, 127.8, 128.4, 128.6, 131.7, 134.2, 135.8, 137.6, 166.2, 170.9; IR (ATR) 3043, 1741, 1678, 1508, 1489 cm^{-1} ; MS (FAB, 3-NBA) 420 (100, $\text{M}+1$); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{26}\text{H}_{29}\text{NO}_4$ ($\text{M}+1$) 420.2157, obsd 420.2156 ($\delta = +0.1$ ppm).

Diels-Alder Adduct(s) 57—To a solution of **54** (100 mg, 0.30 mmol) in toluene (7 mL) was added dimethyl acetylenedicarboxylate (0.1 mL, 0.90 mmol). The reaction mixture was stirred at reflux for 12 h. Then the toluene was evaporated and the crude product was purified by chromatography (30% EtOAc/hexanes) to give **57** (71 mg, 50%); MS (FAB, 3-NBA) 478 ($\text{M}+1$, 45), 105 (100); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{27}\text{H}_{27}\text{NO}_7$ ($\text{M}+1$) 478.1848, obsd 478.1847 ($\delta = +0.3$).

Methyl N-Benzoyl- α -benzyl-L-2',3'-bis(carbomethoxy)phenylglycinate (58)—To a solution of **57** (27 mg, 0.06 mmol) in carbon tetrachloride (0.6 mL) was added bromine (47.9 mg, 0.3 mmol). The reaction mixture was stirred for 1 h at rt. Sodium thiosulfate (1 N) was added and the solution was extracted with EtOAc (3 mL), dried (MgSO_4), filtered, evaporated and chromatographed (30% EtOAc/hexanes) to give the intermediate dibromide(s) (17.3 mg, 55%). To this product in DMF (0.3 mL) was added KOtBu (3.5 mg, 0.03 mmol). The reaction mixture was stirred at rt for 2 h. Then, 0.5N HCl (0.5 mL) was added and the solution was extracted with EtOAc (2×1 mL). The organics were combined, dried (MgSO_4), filtered, evaporated and chromatographed (30% EtOAc/hexanes) to give **58** (12.7 mg, 86%): $[\alpha]_{\text{D}}^{24} +24.4$ (c 0.4, CHCl_3); ^1H NMR (300 MHz, CD_2Cl_2) δ 3.35 (s, 3 H),

3.73 (d, J = 12.6 Hz, 1 H), 3.76 (s, 3 H), 3.81 (s, 3 H), 4.33 (d, J = 12.6 Hz, 1 H), 6.99–7.02 (m, 2 H), 7.19–7.28 (m, 4 H), 7.41, (app t, J = 7.4 Hz, 2 H), 7.51 (app t, J = 7.4 Hz, 1 H), 7.59 (app d, J = 7 Hz, 2 H), 7.66 (t, J = 8.0 Hz, 1 H), 7.96 (d, J = 8.0 Hz, 1 H), 8.14 (d, J = 8.0 Hz, 1 H); ^{13}C NMR (75 MHz, CDCl_3) δ 40.0, 52.2, 53.3, 64.8, 126.9, 127.4, 128.2, 128.4, 129.3, 129.6, 131.6, 131.8, 132.9, 134.2, 134.8, 138.0, 166.9, 167.2, 169.1, 171.2; IR (ATR) 3018, 1747, 1665, 1514, 1482 cm^{-1} ; MS (FAB, 3-NBA) 476 ($M+1$, 24), 154 (100); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{27}\text{H}_{25}\text{NO}_7$ ($M+1$) 476.1709, obsd 476.1708 (δ = +0.2).

Methyl N-Benzoyl- α -1-[[[(4'-acetoxy)-4-phenyl]-E-but-1-en-3-ynyl]-D-phenylalaninate (60)—A solution of **D-47a** (30 mg, 0.05 mmol), 1,1-dibromo-2[4-acetoxyphenyl]ethylene (15.5 mg, 0.05 mmol), diisopropylethylamine (9.4 mg, 0.07 mmol), $\text{Pd}_2(\text{dba})_3$ (1.1 mg, 1.3 μmol) and (p-MeO- C_6H_4) $_3\text{P}$ (3.0 mg, 7.3 μmol) in DMF (0.5 mL) was stirred at 80 $^\circ\text{C}$ for 4 h. Then the reaction mixture was diluted with EtOAc (5 mL) and washed with H_2O (10 mL). The organic layer was dried (MgSO_4), filtered, evaporated and chromatographed (30% EtOAc/hexanes) to give **60** (13 mg, 55%): $[\alpha]_{\text{D}}^{24}$ -67.7 (c 0.2, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 2.28 (s, 3 H), 2.39 (d, J = 13.4 Hz, 1 H), 3.84 (s, 3 H), 3.91 (d, J = 13.4 Hz, 1 H), 5.95 (d, J = 16.1 Hz, 1 H), 6.57 (d, J = 16.1 Hz, 1 H), 7.05–7.11 (m, 5 H), 7.24–7.27 (m, 3 H), 7.45 (d, J = 1.4 Hz, 2 H), 7.47 (d, J = 1.7 Hz, 2 H), 7.55 (app t, J = 7.0 Hz, 1 H), 7.72 (d, J = 7.0 Hz, 2 H); ^{13}C NMR (75 MHz, CDCl_3) δ 21.1, 40.3, 65.7, 111.6, 121.7, 127.0, 127.3, 128.5, 128.7, 129.9, 130.0, 131.8, 132.3, 132.7, 135.1, 140.4, 150.5, 166.4, 171.6, 172.5; IR (ATR) 3031, 1747, 1665, 1595 cm^{-1} ; MS (FAB, 3-NBA) 468 ($M+H$, 100); HRMS (FAB, 3-NBA) m/z calcd for $\text{C}_{25}\text{H}_{25}\text{NO}_5$ ($M+H$) 468.1811, obsd 468.1791 (δ = +4.1 ppm).

Acknowledgments

Financial support from the National Institutes of Health (CA 62034) is gratefully acknowledged. D.B.B. is an Alfred P. Sloan Research Fellow (1997–2001). We thank R. K. Shoemaker for assistance with 2D NMR experiments and R. Cerny (Nebraska Center for Mass Spectrometry) for mass spectral support.

REFERENCES AND NOTES

- Williams, RM. *Synthesis of Optically Active Amino Acids*. Pergamon Press; Oxford: 1989.
- Dardenne G, Casimir J, Marlier M, Larsen PO. *Phytochemistry*. 1974; 13:1897–1900.
- (a) Cho C, Ishii R, Hyeon S, Suzuki A. *Agric Biol Chem*. 1987; 51:2597–2598. (b) Cornell NW, Zuurendonk PF, Kerich MJ, Straight CB. *Biochem J*. 1984; 220:707–716. [PubMed: 6466297] (c) Soper TS, Manning JM, Marcotte PA, Walsh CT. *J Biol Chem*. 1977; 252:1571–1575. [PubMed: 402367] (d) Rando RR, Relyea N, Cheng L. *J Biol Chem*. 1976; 251:3306–3312. [PubMed: 6451] (e) Rando RR. *Biochemistry*. 1974; 13:3859–3863. [PubMed: 4472160]
- Griffith OW. *J Biol Chem*. 1983; 258:1591–1598. [PubMed: 6822523]
- Zabriskie TM, Cheng H, Vederas JC. *J Am Chem Soc*. 1992; 114:2270–2272.
- Laber B, Gerbling K-P, Harde C, Neff K-H, Nordhoff E, Pohlenz H-D. *Biochemistry*. 1994; 33:3413–3423. [PubMed: 7907888]
- Clausen T, Wahl MC, Messerschmidt A, Huber R, Fuhrmann JC, Laber B, Streber W, Steegborn C. *Biol Chem*. 1999; 380:1237–1242. (APPA is said to be a reversible inhibitor in this active site). [PubMed: 10595588]
- For structural mechanistic studies on the mode of GABA transaminase inactivation with a vinyl trigger see: Storici P, Capitani G, De Biase D, Moser M, John RA, Jansonius J, Schirmer T.

- Biochem. 1999; 38:8628–8634. [PubMed: 10393538] Nanavati SM, Silverman RB. J Am Chem Soc. 1991; 113:9341–9349.
9. Jung, MJ., Palfreyman, MG. Vigabatrin. In: Levy, RH., Mattson, RH., editors. Antiepileptic Drugs. 4. Raven Press; New York: 1995.
10. Brennan M. Chem Eng News. Aug 23.1999 :8.
11. For references to the inactivation of AADC's with α -vinyl AA's see: Berkowitz DB, Jahng W-J, Pedersen ML. Bioorg Med Chem Lett. 1996; 6:2151–2156. [PubMed: 29123334]
12. We use the term higher α -vinyl amino acids to designate those members of this family bearing a side chain "higher" than the glycine side chain (i.e. R H).
13. Berkowitz DB, Pedersen ML. J Org Chem. 1995; 60:5368–5369. [PubMed: 29955201]
14. Berkowitz DB, Pedersen ML, Jahng W-J. Tetrahedron Lett. 1996; 37:4309–4312. [PubMed: 29200438]
15. Jahng, WJ., Salud-Bea, R., Berkowitz, DB. ORGN-351. 220th National ACS Meeting; August 20–24, 2000;
16. Mendel D, Ellman J, Schultz PG. J Am Chem Soc. 1993; 115:4359–4360.
17. For studies relating to the incorporation of quaternary AA's into amino acid or peptide libraries, see: Fornicola RS, Oblinger E, Montgomery J. J Org Chem. 1998; 63:3528–3529. Griffith DL, O'Donnell MJ, Pottorf RS, Scott WL, Porco JA Jr. Tetrahedron Lett. 1997; 38:8821–8824. O'Donnell MJ, Zhou C, Scott WL. J Am Chem Soc. 1996; 118:6070–6071.
18. Use of an α -allylated AA for peptide design: Peggion C, Flammengo R, Mossel E, Broxterman QB, Kaptein B, Kamphuis J, Formaggio F, Crisma M, Toniolo C. Tetrahedron. 2000; 56:3589–3601.
19. Theoretical study: Aleman C. J Phys Chem B. 1997; 101:5046–5050. Helical peptide development: Formaggio F, Crisma M, Rossi P, Scrimin P, Kaptein B, Broxterman QB, Kamphuis J, Toniolo C. Chem Eur J. 2000; 6:4498–4504. [PubMed: 11192082] Schafmiester CE, Po J, Verdine GL. J Am Chem Soc. 2000; 122:5891–5892. Mammi S, Rainaldi M, Bellanda M, Schievano E, Peggion E, Broxterman QB, Formaggio Fernando C, Marco, Toniolo C. J Am Chem Soc. 2000; 122:11735–11736. Yokum TS, Gauthier TJ, Hammer RP, McLaughlin ML. J Am Chem Soc. 1997; 119:1167–1168. Jaun B, Tanaka M, Seiler P, Kühnle FNM, Braun C, Seebach D. Liebigs Ann/Recueil. 1997:1697–1710.
20. (a) Medzihradszky-Schweiger, H., Medzihradszky, K., Nadasi, H., Suli-Vargha, H. Proc 25th Eur Pept Symp. Bajusz, S., Hudecz, F., editors. Akademiai Kiado; Budapest: 1999. p. 606–607. (b) Sall, DJ., Shuman, RT., Smith, GF., Wiley, MR. US Patent. 5,484,772. Jul 16, 1996 (c) Frauer A, Mehlführer M, Thirring K, Berner H. J Org Chem. 1994; 59:4215–4222. (d) Veber DF, Freidinger RM. Trends Neurosci. 1985; 8:392–396. (e) Khosla A, Stachowiak K, Smeby RR, Bumpus FM, Piriou F, Lintner K, Femandjian S. Proc Natl Acad Sci USA. 1981; 78:757–760. [PubMed: 6940144]
21. α -Branched AA's in receptor ligands: Rovero P, Pellegrini M, Di Fenza A, Meini S, Quartara L, Maggi CA, Formaggio F, Toniolo C, Mierke DF. J Med Chem. 2001; 44:274–278. [PubMed: 11170638] Yee NK. Org Lett. 2000; 2:2781–2783. [PubMed: 10964364]
22. Branched AA's in peptidyl catalysts: Rossi α -P, Felluga F, Tecilla P, Formaggio F, Crisma M, Toniolo C, Scrimin P. J Am Chem Soc. 1999; 121:6948–6949.
23. Reviews: Cativiela C, Diaz-de-Villegas MD. Tetrahedron: Asymmetry. 1998; 9:3517–3599. Davis FA, Zhou P, Chen B-C. Chem Soc Reviews. 1998; 27:13–18. Wirth T. Angew Chem Int Ed Engl. 1997; 36:225–227. Goodman M, Zhang J. Chemtracts. 1997; 10:629–645. Seebach D, Sting AR, Hoffman M. Angew Chem Int Ed Engl. 1996; 35:2708–2748. Ojima I. Acc Chem Res. 1995; 28:383–389. Duthaler RO. Tetrahedron. 1994; 50:1539–1650.
24. (a) Taylor RJKJS. Chem Commun. 1999:217–227. (b) Larksarp C, Alper H. J Am Chem Soc. 1997; 119:3709–3715. (c) Trost BM, Bunt RC. Angew Chem Int Ed Engl. 1996; 35:99–102. (d) Berkowitz DB, Smith MK. Synthesis. 1996:39–41. (e) Griesbeck AG, Hirt J. Liebigs Ann. 1995:1957–1961. (f) Carrasco M, Jones RJ, Kamel S, Rapoport H, Truong T. Org Syn. 1991; 70:29–34. (g) Pellicciari R, Natalini B, Marinozzi M. Synthetic Commun. 1988; 18:1715–1721. (h) Barton DHR, Crich D, Herve Y, Potier P, Thierry J. Tetrahedron. 1985; 41:4347–4357.

- Hanessian S, Sahoo SP. *Tetrahedron Lett.* 1984; 25:1425–1428.(i) Schöllkopf U, Nozulak J, Groth U. *Tetrahedron.* 1984; 40:1409–1417.
25. (a) Williams RM. *Aldrichimica Acta.* 1992:11–25.(b) Zhai D, Zhai W, Williams RM. *J Am Chem Soc.* 1988; 110:2501–2505.(c) Williams RM, Zhai W. *Tetrahedron.* 1988; 44:5425–5430.
26. (a) O'Donnell MJ, Min Li, Bennett WD, Grote T. *Tetrahedron Lett.* 1994; 35:9383–9386.(b) O'Donnell MJ, Chen N, Zhou C, Murray A, Kubiak C, Yang F, Stanley GG. *J Org Chem.* 1997; 62:3962–3975.
27. (a) Petasis NA, Zavialov IA. *J Am Chem Soc.* 1998; 120:11798–11799.(b) Petasis NA, Zavialov IA. *J Am Chem Soc.* 1997; 119:445–446.
28. Porter JR, Wirschun WG, Kuntz KW, Snapper ML, Hoveyda AH. *J Am Chem Soc.* 2000; 122:2657–2658.
29. For other examples of stereocontrolled syntheses of alkenylglycines, see: Woiwode TF, Wandless TJ. *J Org Chem.* 1999; 64:7670–7674.Griesback AG. *Liebigs Ann.* 1996:1951–1958.Mulzer J, Funk G. *Synthesis.* 1995:101–112.Clayden J, Collington EW, Warren S. *Tetrahedron Lett.* 1993; 34:1327–1330.Mhemandoust M, Petit Y, Larcheveque M. *Tetrahedron Lett.* 1992; 33:4313–4316.Beaulieu PL, Duceppe JS, Johnson C. *J Org Chem.* 1991; 56:4196–4204.Duthaler RO. *Angew Chem Int Ed Engl.* 1991; 30:705–707.Sasaki NA, Hashimoto C, Pauly R. *Tetrahedron Lett.* 1989; 30:1943–1946.Baldwin JE, Moloney MG, North M. *Tetrahedron.* 1989; 45:6319–6330.
30. Groth U, Schöllkopf U, Chiang Y-C. *Synthesis.* 1982:864–866.
31. Weber T, Aeschmann R, Maetzke T, Seebach D. *Helv Chim Acta.* 1986; 69:1365–1377.Seebach D, Bürger HM, Schickli CP. *Liebigs Ann Chim.* 1991:669–684.For a recent example, that melds Seebach's SRS approach and formal α -vinylation, see: Ma D, Zhu W. *J Org Chem.* 2001; 66:348–350. [PubMed: 11429926]
32. (a) Colson PJ, Hegedus LS. *J Org Chem.* 1993; 58:5918–5924.(b) Ojima I, Komata T, Qiu X. *J Am Chem Soc.* 1990; 112:770–774.
33. (a) Avenoza A, Cativiela C, Corzana F, Peregrina JM, Zurbano MM. *J Org Chem.* 1999; 64:8220–8225. [PubMed: 11674740] (b) Avenoza A, Cativiela C, Peregrina JM, Sucunza D, Zurbano MM. *Tet: Asymmetry.* 1999; 10:4653–4661.
34. Sharpless, KB. *Asymmetric Synthesis.* Vol. 5. Academic Press; New York: 1985. p. 247–308.
35. Hatakeyama S, Matsumoto H, Fukuyama H, Mukugi Y, Irie H. *J Org Chem.* 1997; 62:2275–2279. [PubMed: 11671543]
36. For another approach to a quaternary, α -vinyl AA involving the Beckmann rearrangement, see: Westermann B, Gedrath I. *Synlett.* 1996:665–666.
37. Pedersen ML, Berkowitz DB. *J Org Chem.* 1993; 58:6966–6975.Pedersen ML, Berkowitz DB. *Tetrahedron Lett.* 1992; 33:7315–7318.For important early work on phenylselenolate-mediated lactone cleavage, see: Liotta D, Sunay U, Santiesteban H, Markiewicz W, Yoneda F, Kuroda K. *J Org Chem.* 1981; 46:2605–2610.Scarborough RM Jr, Toder BH, Smith AB III. *J Am Chem Soc.* 1980; 102:3904–3913.
38. Berkowitz DB, Pumphrey JA, Shen Q. *Tetrahedron Lett.* 1994; 35:8743–8747.
39. Dumas F, Mezrhah B, d'Angelo J. *J Org Chem.* 1996; 61:2293–2304. and refs therein.
40. Berkowitz DB, McFadden JM, Sloss MK. *J Org Chem.* 2000; 65:2907–2918. [PubMed: 10814177]
41. Gassman PG, Schenk WN. *J Org Chem.* 1977; 42:918–920.
42. Berkowitz DB, McFadden JM, Chisowa E, Semerad CL. *J Am Chem Soc.* 2000; 122:11031–11032. Though we are aware of no examples of the direct conversion of vinyl selenides to vinyl stannanes prior to this work, there had been reports of the conversion of vinyl sulfones or vinyl sulfides to vinyl stannanes (see this reference for such citations).
43. To our knowledge there had only been one isolated report of a quaternary stannylvinyl AA prior to this work: Sewald N, Gaa K, Burger K. *Heteroatom Chem.* 1993; 4:253–258.
44. For examples of the synthesis and use of *glycine* derivatives bearing alkenylstannane functionality, see: Kazmaier U, Schauss D, Pohlman M, Raddatz S. *Synthesis.* 2000:914–916.Reginato G, Mordini A, Valacchi M, Grandini E. *J Org Chem.* 1999; 42:9211–9216.Reginato G, Mordini A, Caracciolo M. *J Org Chem.* 1997; 62:6187–6192.Crisp GT, Gebauer MG. *Tetrahedron Lett.* 1995; 36:3389–3392.Crisp GT, Glink PT. *Tetrahedron.* 1994; 50:3213–3234.
45. Sheffy FK, Godschaalx JP, Stille JK. *J Am Chem Soc.* 1984; 106:4833–4840.

46. Milstein D, Stille JK. J Am Chem Soc. 1979; 101:4992–4998.
47. For examples of the synthesis and use of *glycine* derivatives bearing iodoalkenyl functionality, see: Crisp GT, Glink PT. Tetrahedron. 1994; 50:2623–2640.
48. Amatore C, Jutand A. Acc Chem Res. 2000; 33:314–321. [PubMed: 10813876]
49. (a) Negishi, E-I. Organozinc Reagents. Knochel, P., Jones, P., editors. Oxford University Press; Oxford, UK: 1999. p. 213-243.(b) Negishi E-I, Takahashi T, Baba S. Org Synth. 1987; 66:60–66. and refs therein.
50. Rieke RD. Aldrichimica Acta. 2000; 33:52–60.
51. Sonagashira K, Tohda Y, Hagihara N. Tetrahedron Lett. 1975; 16:4467–4470.
52. Shen W, Wang L. J Org Chem. 1999; 64:8873–8879. [PubMed: 11674792]

Scheme 1.

Novel Quaternary AA's from α -Vinyl AA's:

Scheme 2.

Scheme 3.

Scheme 4.

Scheme 5.

Scheme 6.

Scheme 7.

Scheme 8.

Scheme 9.

Hatakeyama/Avenoza & Cativiela **Scheme 10.**

Berkowitz, Pedersen, Pumphrey & Shen
 Formal Vinylation of Amino Acids - Kinetic Enzymatic Resolution

Scheme 11.

Berkowitz, McFadden and Sloss

Acyclic Stereocontrol: Alkylation of Chiral Vinylglycine-Based Dienolates

Scheme 12.

Berkowitz, McFadden and Chisowa
A New SRS Approach: Access to D- or L-Stannylvinyl AA's

index	alkyl halide	AA analogue	%ee	alkyl. yield	unmask yield	subst. yield	deprot. yield
a	BnBr	L-Phe	99	90%	76%	84%	85%
a	BnBr	D-Phe	>99	80%	70%	80%	---
b	CH ₃ I	L-Ala	99	82%	77%	87%	83%
b	CH ₃ I	D-Ala	>99	79%	71%	85%	90%
c	BnOCH ₂ Br	L-Ser	99	80%	80%	85%	98%
c	BnOCH ₂ Br	D-Ser	99	90%	75%	74%	---
d	EtO ₂ CCH ₂ Br	L-Asp	99	86%	74%	85%	82%
e	ICH ₂ C ₆ H ₄ - <i>m</i> -OTBS	L- <i>m</i> -Tyr	98	90%	75%	83%	91%
f	E-PhCH=CHCH ₂ Br	L-Cinn-Gly	>99	78%	---	---	---

Scheme 13.

Facile Stereospecific Introduction of a Deuterium Label **Scheme 14.**

Stille Couplings of the Quaternary, Stannylvinyl AA's

Scheme 15.

Ready Access to a Complementary Set of Cross-Coupling Partners:
Quaternary α -(2-Iodo)vinyl AA's

Scheme 16.

Reversed Polarity Pd-Catalyzed Couplings . . .

Scheme 17.

Diels-Alder Chemistry Along the α -Branch . . . **Scheme 18.**

Scheme 19.